Summary

Cell and Gene Therapy Market Research Report Information by Therapy Type (Cell Therapy and Gene Therapy), Application (Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032

Market Overview
The Cell and Gene Therapy Market size was valued at USD 12.83 billion in 2023 and is projected to grow from USD 15.01 billion in 2024 to USD 67.89 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.12% during the forecast period (2024 - 2032). The growing incidences of cancer and rare disorders and increasing approval for gene and cell therapy products are major factors driving the market growth.
Increasing incidences of diseases such as cancer, cystic fibrosis, sickle cell anaemia, and others, are burgeoning market growth. Thus, the increasing incidences of cancer and rare disorders across the globe and rising innovative product launches to treat these diseases are boosting the growth of the market.
Favorable regulatory authorities play an important role because these treatments are more widely accepted by healthcare professionals, patients, and regulatory bodies. Frequent approval increases the number of patients willing to consider these therapies. Furthermore, there are clear pathways for regulatory approval due to the increased use of cell and gene therapy.
Market Segment Insights
Based on therapy type, the global cell & gene therapy market has been segmented into cell therapy and gene therapy.
Based on application, the global cell & gene therapy market has been segmented into Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders, and Others.
Regional Insight

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

Based on region, the global cell & gene therapy market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share of 42.68% in 2022 and is anticipated to reach approximately USD 27.01 billion by 2032 at a 17.38% CAGR during the forecast period, owing to rise in the prevalence of chronic disease, availably of reimbursements for the gene therapy and rise in healthcare expenditure and research development activities for gene therapy drugs across the region. In North America, US dominated the market with market share of 82.36%.
However, Asia-Pacific is projected to grow at the highest CAGR of 20.10% during the forecast period, owing to a sizable population base, heightened healthcare awareness, and a surge in cases of cancer. These factors collectively drive the demand for gene therapy in the region. Additionally, pharmaceutical market expansion, government initiatives, and a surge in research and development activities contribute to the region's accelerated growth. Furthermore, a rise in research activities as well as the well-established presence of domestic companies in the region are expected to provide notable opportunities for market growth. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Japan dominated the market in Asia-Pacific region with market share 24.55%.
Major Players
Key Companies in the Cell and Gene Therapy Market include Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), and Janssen Global Services (US).

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Type
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Growing incidences of Cancer and rare disorders
4.2.2 Increasing approval for Gene and Cell therapy Products
4.3 RESTRAINTS
4.3.1 Clinical Trial Failure associated with gene and cell therapy
4.4 OPPORTUNITY
4.4.1 Growing investment in the field of gene and cell therapy
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL CELL AND GENE THERAPY MARKET
6 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE
6.1 OVERVIEW
6.2 CELL THERAPY
6.2.1 Autologous
6.2.2 Allogeneic
6.3 GENE THERAPY
6.3.1 Ex vivo
6.3.2 In vivo
7 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 CANCER
7.3 NEUROLOGICAL DISORDERS
7.4 CARDIOVASCULAR DISORDERS
7.5 RARE DISEASES
7.6 OPHTHALMOLOGY
7.7 BLOOD DISORDERS
7.8 OTHERS
8 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 Germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 ASIA-PACIFIC
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-pacific
8.5 REST OF THE WORLD
8.5.1 Middle East & Africa
8.5.2 South America
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2022
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 product launch / Product approval
9.6.2 Collaboration
9.6.3 Agreement
9.6.4 Expansion
10 COMPANY PROFILES
10.1 NOVARTIS AG
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 products OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 BRISTOL-MYERS SQUIBB COMPANY
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 products OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 AMGEN INC.
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 productS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 AURION BIOTECH
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 productS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 SAREPTA THERAPEUTICS, INC.
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 productS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 FERRING B.V.
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 products OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 SIBIONO GENETECH CO. LTD., SHENZHEN (SIBIONO)
10.7.1 COMPANY OVERVIEW
10.7.2 products OFFERED
10.7.3 KEY DEVELOPMENTS
10.7.4 KEY STRATEGIES
10.8 BLUEBIRD BIO, INC.
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT Analysis
10.8.6 KEY STRATEGIES
10.9 KITE PHARMACEUTICALS, INC.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT Analysis
10.9.6 KEY STRATEGIES
10.10 JANSSEN GLOBAL SERVICES
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 Products OFFERed
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 DATA CITATIONS